Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study.

ABSTRACT:

Introduction

Patients with severe allergic asthma (SAA) are at risk of severe exacerbations. Omalizumab is recommended as an add-on treatment for patients with uncontrolled SAA, despite high-dose inhaled corticosteroids and long acting β₂-agonist combination therapy (standard therapy).RELIEF was a prospective, open label, multicenter study conducted to assess the real-life effectiveness of omalizumab co-administered with standard therapy in patients with SAA for 24 months.

Methods

A total of 347 patients aged ≥ 6 years with SAA were enrolled, 285 of whom (8 pediatrics and 277 adolescents and adults) completed this 24-month study. Compared with the 12 months prior to baseline, the mean number of exacerbations was reduced in the overall population at any time interv

SUBMITTER: Al Ahmad M 

PROVIDER: S-EPMC10156055 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature